AstraZeneca and Mersadon release Phase III clinical study data for targeted cancer drug Lynparza

Recently, AstraZeneca and partner Mersadon released positive data on the evaluation of phase III clinical research PROfound, a targeted cancer drug, Lynparza (Lipjo, olaparib, )This assessment was primarily used by Lynparza to treat male patients with metastatic prostate cancer who were involved in the treatment of homologous recombinant repair gene mutations (HRRm) in tumors and had previously received a new hormone anticancerdrug(http://treating the progression of the diseaseAbout LynparzaLynparza is a first-time oral polypolyaDP ribonucleopolymerase (PARP) inhibitor that prioritizes the use of defects in the tumor DNA damage repair (DDR) pathway to kill cancer cells, a mode of action that gives Lynparza the potential to treat a wide range of types of tumors with DNA damage repair defectson PROfound
PROfound is a forward-looking, multicenter, randomized, open label Phase IIItrial(http://in male patients who were previously treated with new hormone anticancer drugs and whose tumors were present with a qualified tumor mutation in one of the 15 genes involved in the HRR signaling pathway, including BRCA1/2, ATM, and CDK12The study assessed the efficacy and safety of Lynparza in relation to the standard nursing drug Xtandi (enzalutamide, enmelua) or Zytiga (abiraterone acetate, acetate acetaminophen)The results showed that in mCRPC patients with BRCA1/2 or ATM mutations in tumor gene screening, Lynparza achieved statistically significant and clinical improvements in radiology without progression (rPFS) compared to Xtandi or ZytigaIn terms of safety
In this study, Lynparza's safety and tolerance were broadly consistent with previous clinical trials